. Dexamethasone prevents virus-induced hyperresponsiveness via multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 285: L451-L455, 2003. First published April 25, 2003 10.1152/ajplung.00046.2003In the lungs, neuronal M2 muscarinic receptors inhibit acetylcholine release from the parasympathetic nerves. Parainfluenza virus infection causes loss of M2 receptor function, which increases acetylcholine release and vagally mediated bronchoconstriction. Because glucocorticoids are known to inhibit airway hyperresponsiveness, we tested whether dexamethasone (6.5 or 65 g/kg ip) prevents virus-induced hyperresponsiveness and M2 receptor dysfunction in guinea pigs. In controls, pilocarpine, a muscarinic agonist, inhibited vagally induced bronchoconstriction, demonstrating functional M 2 receptors. However, in virus-infected animals, pilocarpine failed to inhibit vagally induced bronchoconstriction, demonstrating M2 receptor dysfunction. Frequency-dependent bronchoconstriction was greater in virus-infected animals than in controls, indicating airway hyperresponsiveness. Low-dose dexamethasone (6.5 g/kg ip) treatment prevented virus-induced airway hyperresponsiveness, ameliorated M2 receptor dysfunction, and decreased viral content in the lungs without inhibiting virus induced inflammation. High-dose dexamethasone (65 g/kg ip) prevented virus-induced hyperresponsiveness, completely reversed M 2 receptor dysfunction, decreased viral titers, and decreased virus-induced inflammation. This highdose dexamethasone also increased M2 receptor function in uninfected animals. In conclusion, dexamethasone prevented virus-induced hyperresponsiveness and M2 receptor dysfunction via multiple mechanisms.
Because glucocorticoids are known to inhibit airway hyperresponsiveness, we tested whether dexamethasone (6.5 or 65 g/kg ip) prevents virus-induced hyperresponsiveness and M2 receptor dysfunction in guinea pigs. In controls, pilocarpine, a muscarinic agonist, inhibited vagally induced bronchoconstriction, demonstrating functional M 2 receptors. However, in virus-infected animals, pilocarpine failed to inhibit vagally induced bronchoconstriction, demonstrating M2 receptor dysfunction. Frequency-dependent bronchoconstriction was greater in virus-infected animals than in controls, indicating airway hyperresponsiveness. Low-dose dexamethasone (6.5 g/kg ip) treatment prevented virus-induced airway hyperresponsiveness, ameliorated M2 receptor dysfunction, and decreased viral content in the lungs without inhibiting virus induced inflammation. High-dose dexamethasone (65 g/kg ip) prevented virus-induced hyperresponsiveness, completely reversed M 2 receptor dysfunction, decreased viral titers, and decreased virus-induced inflammation. This highdose dexamethasone also increased M2 receptor function in uninfected animals. In conclusion, dexamethasone prevented virus-induced hyperresponsiveness and M2 receptor dysfunction via multiple mechanisms.
M2 receptor function; glucocorticoids; vagus nerves; asthma RESPIRATORY VIRAL INFECTIONS are an important cause of asthma attacks (13) . Viral infections account for 80-85% of asthma exacerbations in children (17) and 50-55% in adults (4). Virus-induced hyperresponsiveness in animals and humans is blocked by atropine, indicating a role for the parasympathetic nerves (3, 6, 8) .
In the lungs, acetylcholine released from parasympathetic nerves onto postjunctional M 3 muscarinic receptors causes smooth muscle contraction and bronchoconstriction. Acetylcholine also binds to inhibitory prejunctional M 2 muscarinic receptors on parasympathetic nerves, suppressing acetylcholine release and decreasing vagally induced bronchoconstriction (5, 9) . Blocking these neuronal M 2 receptors with selective antagonists such as gallamine causes a 5-to 10-fold increase in vagally induced bronchoconstriction (1, 9, 10) . Conversely, stimulating neuronal M 2 muscarinic receptors with muscarinic agonists, such as pilocarpine, inhibits vagally induced bronchoconstriction (9) .
During viral infection, neuronal M 2 receptors are dysfunctional (2, 11) . Both viral infection and interferon-␥ (which is produced in response to viruses) decrease expression and function of the M 2 receptors in cultured airway parasympathetic nerves from guinea pig trachea (14) . The glucocorticoid dexamethasone increases expression of M 2 receptors in these cells in culture and can prevent the interferon-induced decrease in M 2 receptor expression in vitro (16) .
These experiments were designed to test whether dexamethasone prevents virus-induced hyperresponsiveness and M 2 receptor dysfunction in vivo. Viral infection and dexamethasone treatment. Pathogenfree guinea pigs were anesthetized with ketamine (30 mg/kg im) and xylazine (5 mg/kg im) and infected with parainfluenza virus type 1 (Sendai virus, ATCC-VR 105) intranasally on day 0 with 10 5 TCID50/ml. [TCID50 is defined as the amount of virus required to infect 50% of monolayers of cultured rhesus monkey kidney cells (15) ]. Two and three days after infection, animals were treated with dexamethasone (6.5 or 65 g/kg ip). Dexamethasone was also administered to noninfected controls. On day 4, 24 h after the last dose of dexamethasone, M 2 receptor function, airway hyperresponsiveness, inflammation, and lung viral content were assessed.
METHODS

Animals
Measurements of pulmonary inflation pressure. Guinea pigs were anesthetized with urethane (1.5 g/kg ip). Blood pressure and heart rate were recorded from the carotid artery. The trachea was cannulated, and the guinea pigs were paralyzed with succinylcholine (10 g/kg/min iv), treated with guanethidine (20 mg/kg iv) to deplete catecholamines, thereby eliminating sympathetic effects of vagal stimulation, and ventilated at a respiratory rate of 100 breaths/min and 10 ml/kg tidal volume. Pulmonary inflation pressure (Ppi) was measured from a side arm of the tracheal cannula. Bronchoconstriction (mmH 2O) was measured as an increase in Ppi.
Studies of vagal hyperresponsiveness. Both vagus nerves were cut, and the distal ends were placed on platinum electrodes. Electrical stimulation of both vagus nerves (10 V, 0.2-ms pulse, 2-25 Hz, for 5 s at 120-s intervals) produced reversible bronchoconstriction and bradycardia that were blocked with atropine (1 mg/kg).
Test for neuronal M 2 muscarinic receptor function with pilocarpine. We produced reproducible bronchoconstriction by stimulating both vagus nerves (2 Hz, 0.2-ms pulse, for 22 s at 1-min intervals). Voltage was chosen within the range of 10-30 V to give an increase in Ppi of 12-15 mmH 20. M2 receptor function was measured as the ability of the muscarinic agonist pilocarpine (0.1-100 g/kg iv) to inhibit vagally induced bronchoconstriction. Data are expressed as the ratio of the bronchoconstriction in the presence of pilocarpine to the bronchoconstriction in the absence of pilocarpine.
Response of the airways to acetylcholine. We tested the function of M3 muscarinic receptors on airway smooth muscle in vagotomized guinea pigs by measuring bronchoconstriction induced by intravenous acetylcholine (1-10 g/kg).
Bronchoalveolar lavage. At the end of each experiment, bronchoalveolar lavage was collected from each animal. In brief, lungs were lavaged with 10 ml of PBS via the tracheal cannula. The recovered fluid was centrifuged at 400 g for 5 min. The cells were resuspended in 10 ml of PBS and counted in a hemocytometer (Hausser Scientific). Aliquots of this cell suspension were cytospun onto glass slides and stained with Diff-Quik (Baxter Healthcare) and counted to obtain differential cell counts.
Titration of virus in lungs.
Infection was confirmed in all virus-infected animals as previously described (2) . After physiological studies were completed, the guinea pig lungs were removed, weighed, and homogenized in 2 ml of PBS (Polytron, Brinkmann). We eluted virus from the tissue homogenate by incubating it at 37°C for 1 h. The suspension was centrifuged at 1,500 rpm for 30 min, and the supernatants were inoculated in serial 10-fold dilutions into rhesus monkey kidney cell monolayers. After incubation at 34°C for 1 wk, the monolayers were washed, and the medium was replaced with a 0.5% suspension of guinea pig red blood cells in Hanks' buffered salt solution. After 1 h at 4°C, the red blood cells were washed off, and the monolayers examined under an inverted phase-contrast microscope for evidence of hemadsorption (adhesion of erythrocytes to monolayers because of the expression of viral hemagglutinin on infected cell membranes). Viral content was determined as the amount of lung homogenate required to produce infection in 50% of rhesus monkey kidney cell monolayers (the TCID50) and is expressed as TCID50/g lung wet weight.
Drugs. Acetylcholine, atropine, dexamethasone, guanethidine, ketamine, pilocarpine, succinylcholine, urethane, and xylazine were purchased from Sigma Chemical.
Data analysis. All data were expressed as the means Ϯ SE. Dose-response curves were compared by analysis of variance (ANOVA) for repeated measures. Multiple comparisons among means for bronchoalveolar lavage and virus titers were done with ANOVA (Statview, 4.51; Abacus Concepts).
RESULTS
Baselines.
Baseline heart rate (318.5 Ϯ 27.7 beats/ min) and blood pressure (systolic blood pressure 52.5 Ϯ 9.4 mmHg, diastolic blood pressure 36.2 Ϯ 8.5 mmHg) in controls were not changed either by viral infection or by dexamethasone. Ppi was significantly increased in virus-infected guinea pigs (control, 100 Ϯ 5 mmH 2 0 vs. virus, 150 Ϯ 8 mmH 2 0). Dexamethasone (6.5 or 65 g/kg ip) did not inhibit the virus-induced increase in resting Ppi.
Effect of dexamethasone on vagally induced bronchoconstriction. Electrical stimulation of both vagus nerves caused frequency-dependent bronchoconstriction that was significantly potentiated in virus-infected animals (Fig. 1) . Dexamethasone (6.5 g/kg ip) prevented virus-induced potentiation of vagally induced bronchoconstriction but did not change vagally induced bronchoconstriction in controls. (Fig. 1) . Stimulation of the nerves also caused a frequency-dependent fall in heart rate. Neither viral infection nor dexamethasone altered vagally induced bradycardia (data not shown).
Effect of dexamethasone on neuronal M 2 muscarinic receptor function. Electrical stimulation of the vagi was done with voltages (10-30 V) that were adjusted to yield similar bronchoconstrictions in all groups. Pilocarpine (0.1-100 g/kg iv) inhibited vagally induced bronchoconstriction in control animals, in a dose-related manner, due to stimulation of the neuronal M 2 receptors (Fig. 2) . In contrast, pilocarpine did not decrease vagally mediated bronchoconstriction in virusinfected animals, indicating dysfunctional M 2 receptors (Fig. 2) . In virus-infected animals treated with 6.5 g/kg dexamethasone, pilocarpine partially inhibited vagally mediated bronchoconstriction ( Fig. 2A) , whereas in those treated with 65 g/kg iv dexamethasone, the inhibition of vagally induced bronchoconstriction by Fig. 1 . Virus-induced hyperresponsiveness is prevented by dexamethasone. Electrical stimulation (10 V, 0.2 ms, 5 s) of both vagi caused frequency-dependent bronchoconstriction, measured as an increase in pulmonary inflation pressure (Ppi) in controls (E). This is not affected by treatment with dexamethasone (Dex; 6.5 g/kg ip, ᮀ). Vagally induced bronchoconstriction was significantly potentiated by viral infection (F, P Ͻ 0.05). Dex completely prevented virus-induced hyperresponsiveness (s); n ϭ 5-8.
pilocarpine was not different from uninfected controls (Fig. 2B) . However, whereas 6.5 g/kg iv dexamethasone had no effect on the ability of pilocarpine to inhibit vagally mediated bronchoconstriction in uninfected animals ( Fig. 2A) , 65 g/kg iv dexamethasone increased the response to pilocarpine in uninfected guinea pigs (Fig. 2B) , indicating a hyperfunctional M 2 receptor.
Effect of dexamethasone on intravenous acetylcholine-induced bronchoconstriction. Intravenous acetylcholine caused a dose-related bronchoconstriction (1-10 g/kg) that was not altered by viral infection or by dexamethasone (Fig. 3) . In addition, acetylcholine also caused a fall in heart rate that was not affected by viral infection or dexamethasone (data not shown).
Effect of dexamethasone on inflammatory cells. Macrophages and neutrophils in bronchoalveolar lavage
were significantly increased in lungs of guinea pigs infected with parainfluenza virus (Fig. 4) . The lower dose of dexamethasone (6.5 g/kg ip) did not inhibit virus-induced inflammation. In contrast, the higher dose of dexamethasone (65 g/kg ip) inhibited virusinduced increase in inflammatory cells in bronchoalveolar lavage.
Effect of dexamethasone on viral infection of the lungs. Both 6.5 and 65 g/kg ip dexamethasone significantly decreased the amount of virus recovered from infected guinea pig lungs (Fig. 5) . In addition, a significant correlation between viral titer and maximal response to pilocarpine was found (Fig. 6 ).
DISCUSSION
We (2) and others (6) have previously shown that parainfluenza virus infection of guinea pigs causes F, A and B) . Dex at 6.5 g/kg ip partially restored M2 receptor function (s, A), whereas Dex at 65 g/kg ip (OE, B) completely restored M2 receptor function in virusinfected animals. Although 6.5 g/kg Dex had no effect in controls (ᮀ, A), 65 g/kg ip significantly increased the ability of pilocarpine to suppress vagally induced bronchoconstriction, indicating an increase in M2 receptor function (‚, B). *P Ͻ 0.05; n ϭ 5-8. hyperresponsiveness to vagal stimulation. This hyperresponsiveness is at the level of increased acetylcholine release from the nerves, as bronchoconstriction to exogenous acetylcholine is not increased by viral infection. Viral infection causes dysfunction of M 2 muscarinic receptors, resulting in increased release of acetylcholine (2).
Dexamethasone (6.5 g/kg) prevented virus-induced hyperresponsiveness ( Fig. 1) and partially restored M 2 receptor function (Fig. 2) . This dose of dexamethasone did not affect either the airway response to vagal stimulation or M 2 receptor function in uninfected guinea pigs. A higher dose of dexamethasone (65 g/kg) completely prevented virus-induced M 2 receptor dysfunction (Fig. 2) . However, as we have previously shown, treatment with high-dose dexamethasone increased M 2 receptor function in uninfected guinea pigs (16) .
Virus infection induces inflammation in the lungs, consisting primarily of macrophages and neutrophils (Fig. 4) . Although the higher dose of dexamethasone reduced virus-induced inflammation in the lungs, the lower dose of dexamethasone did not change virusinduced inflammation. Despite this lack of effect on inflammation, low-dose dexamethasone prevented virus-induced hyperresponsiveness and partially prevented virus-induced M 2 receptor dysfunction. Thus the protective effects of low-dose dexamethasone on responsiveness and M 2 receptor function are not dependent on suppression of inflammation.
Both doses of dexamethasone reduced viral content of the lungs. This antiviral effect was greater with the higher dose of dexamethasone than with the lower dose. Viral titers correlated inversely with M 2 receptor function (Fig. 6) , suggesting that suppression of viral replication may contribute to the protective effects of dexamethasone on M 2 receptor function.
Thus there may be multiple mechanisms by which dexamethasone prevents virus-induced airway hyperresponsiveness. First, dexamethasone may have a direct effect on the M 2 receptor, increasing expression and function (16) and thereby compensating for virusinduced M 2 receptor dysfunction. Consistent with this possibility is our observation that, although interferon-␥ decreases M 2 receptor expression and function in nerve cell cultures, these effects can be reversed by dexamethasone (16) . Second, dexamethasone has an anti-inflammatory effect, and high doses of dexamethasone can attenuate virus-induced inflammation. Third, dexamethasone suppresses viral replication in the lungs. The more complete reversal of virus-induced M 2 receptor dysfunction with the higher dose of dexamethasone may suggest that all these mechanisms contribute to the beneficial effects of dexamethasone.
We have previously shown that blocking the inflammatory response to viral infection (using cyclophosphamide) prevents M 2 receptor dysfunction in some, but not all, virus-infected animals (12) . It is likely to be significant that, in those animals that were treated with cyclophosphamide, animals with high viral content in the lungs were the ones that lost M 2 receptor function, whereas those with lower viral content had normal M 2 receptor function. This supports our hypothesis that the antiviral effect of dexamethasone contributes to inhibiting virus-induced hyperresponsiveness in the present study, as viral content correlated inversely with M 2 receptor function.
There have been few other reports of antiviral effects of glucocorticoids. Kimsey and colleagues (18) reported that pretreating hamsters with steroids prevents subsequent infection with parainfluenza virus. Although the mechanism of this effect is not known, they speculate that decreased viral receptors on epithelial cells might be responsible. Decreased viral receptors ac- counts for the antiviral effects of steroids on infectability of cultured epithelial cells with rhinovirus (19) . In this case, expression of ICAM-1, the receptor for most rhinoviruses, was suppressed by steroid pretreatment. In contrast, Domachowske and colleagues (7) showed that treating mice with steroids increases titers of pneumonia virus of mice (a virus related to human respiratory syncytial virus). They speculate that this might be due to an antiviral effect of eosinophils in this infection and the suppression of eosinophilia by the steroid treatment. Pretreatment of rhesus monkey kidney cells with dexamethasone inhibits the ability of parainfluenza virus to grow in these cells (Moreno L, Jacoby DB, and Fryer AD, unpublished observations), supporting our in vivo observation that dexamethasone is antiviral.
Thus dexamethasone reverses virus-induced airway hyperresponsiveness and M 2 muscarinic receptor dysfunction via multiple mechanisms. High-dose dexamethasone suppresses virus-induced inflammation and decreases viral replication. At high doses, dexamethasone also increases M 2 receptor function in uninfected animals, possibly by increasing M 2 receptor gene expression (16) . All these effects may contribute to the protective effects of high-dose dexamethasone in virus-infected airways. In contrast, low-dose dexamethasone also prevents virus-induced hyperresponsiveness. However, it does so without inhibiting virusinduced inflammation or increasing expression of M 2 receptors in uninfected animals. It partially restores M 2 receptor function, possibly by decreasing viral titers, and this is sufficient to prevent virus-induced hyperresponsiveness.
Glucocorticoids are part of the standard treatment for acute asthma attacks. In view of multiple studies showing that viral infections are a major cause of asthma attacks, it is important to consider the effects of this treatment on both virus-induced hyperresponsiveness and viral replication in the lungs. The results of this study show that glucocorticoids ameliorate virus-induced hyperresponsiveness via multiple mechanisms and that they restore the function of M 2 receptors in virus-infected airways. Furthermore, at least for parainfluenza virus, treatment with glucocorticoids not only does not hamper the body's ability to contain the infection but actually reduces viral replication in the lungs. This may have implication not only for the management of asthma attacks but also for the overall strategies of managing viral infections of the lungs.
